

Period (起止时间)

Dec, 2019-_x001f_-- present Dec, 2013- x001f -- Dec, 2019

Oct, 2007- x001f -- Dec, 2013

Aug, 1998- x001f -- Oct, 2007

Period (起止时间)

Sept, 2009--- July, 2012

Sept, 2002--- July, 2005

Sept, 1993--- July,1998

Name (中英文姓名): 林根 Gen Lin

1110				
Institute (学院):		Deparment (科室):	Department of Thoracic Oncology	
Professional Title (专业职称):	Chief Physician	Teaching Title (教学职称):	Adjunct Vice Professo	
Contact (联系方式): _		E-mail (电子邮箱):_	lingen197505@163.com	

Work Experience (工作经历)

Institution/University、City、Country(国家/大学/机构/职称)

Chief physician, Fujian cancer Hospital, Fuzhou, China Deputy chief physician, Fujian cancer Hospital, Fuzhou, China Attending Doctor, Fujian cancer Hospital, Fuzhou, China Resident Doctor, Fujian cancer Hospital, Fuzhou, China

Education(教育背景)

When&where to obtain the highest degree (何时何校获最高学位及学历)

University, City, Country (国家/大学/最高学位)

Ph.D. in Medical Oncology, Fujian Medical University, Fujian, China M.M. in Medicine, Fujian Medical University, Fujian, China B.M. in Chinese Traditional Medicine, Beijing University of Chinese Medicine, Beijing, China

Overseas Experience出国经历

including study, research and foreign aid (含留学、援外、研修)

Period (起止时间)

Institution/University, City, Country (国家/大学/机构/职称)

Major & Research Direction (招生专业及研究方向)

Displine Level I (一级学科)	Displine Level II&III (专业名称:二科+三级学科)	Research Direction (研究方向及专长)	Level (层次)	Type (学位类型)
Medicine	internal Medicine (respiratory medicine)	precision medicine in lung cancer	☑P.H.D/M.D ☑Master	☑ Academic ☑ Professional
			□P.H.D/M.D □Master	☐Academ ☐Professional

Personal Profile (基本情况简介)

(around 150 words, including basic introduction, research direction, teaching experience as supervisor for international students)

Gen Lin is the Director of Department of Thoracic Oncology at the Fujian cancer Hospital, which is the cancer treatment center in Fujian Province in China. He also serve as President of the Professional Committee on lung cancer of Fujian anti-cancer Association. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He have led and co-led multiple-center clinical studies, which address various aspects on management of advanced lung cancer, and basically have defined the current practice. He has contributed to over 60 articles in international peer-reviewed journals, including Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer, and Frontiers in imunology, and published multiple editorials and textbooks. His work was recognised by numerous awards including Outstanding Contribution Award on lung cancer in 2019 in China.